
    
      This is a multicentre randomised controlled clinical trial conducted in China to compare the
      efficacy and and safety of Anlotinib vs Docetaxel in patients of EGFR mutation-negative
      advanced nonsquamous non-small Cell Lung Cancer.

      Eligible patients will be randomized to arm A and arm B:

      Arm A: Patients on the anlotinib arm received 12mg anlotinib orally daily on day 1 to 14 of a
      21-day cycle.

      Arm B: Patients on the docetaxel arm received 75mg/m2 docetaxel as intravenous infusion on
      day 1 of a 21-day cycle.
    
  